Crinetics intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and investment securities, to fund research and development of its ...

Sacubitril/valsartan significantly reduces NT-proBNP levels in patients with heart failure with reduced ejection fraction (HFrEF) over 3 years, with no significant changes in sST2 and galectin-3.

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option ...